Lars Koch Hansen, Karina Winther Andersen, Sara Emmerich Jensen, Michael Dam Jensen
{"title":"注射英夫利昔单抗或维多单抗后无反应。","authors":"Lars Koch Hansen, Karina Winther Andersen, Sara Emmerich Jensen, Michael Dam Jensen","doi":"10.61409/A03250206","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Biologic therapies like infliximab and vedolizumab effectively treat inflammatory bowel disease (IBD), but post-infusion observation consumes considerable clinical resources. This study evaluated whether post-infusion observation periods may be safely reduced or eliminated.</p><p><strong>Methods: </strong>A retrospective analysis included all IBD patients receiving infliximab or vedolizumab from January 2019 to December 2020 at Sygehus Lillebaelt, Denmark. Data included infusion counts, observation duration, timing and severity of reactions.</p><p><strong>Results: </strong>Among 380 patients receiving 3,847 infusions, 43 reactions (1.1%) occurred exclusively during infusions, mostly within the first 15 minutes. No reactions were reported after infusion had concluded.</p><p><strong>Conclusions: </strong>Routine post-infusion observation after infliximab and vedolizumab appears unnecessary. Reducing or eliminating this practice may optimise clinical resources without compromising patient safety.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Not relevant.</p>","PeriodicalId":11119,"journal":{"name":"Danish medical journal","volume":"72 10","pages":""},"PeriodicalIF":1.2000,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"No post-infusion reactions after infliximab or vedolizumab.\",\"authors\":\"Lars Koch Hansen, Karina Winther Andersen, Sara Emmerich Jensen, Michael Dam Jensen\",\"doi\":\"10.61409/A03250206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Biologic therapies like infliximab and vedolizumab effectively treat inflammatory bowel disease (IBD), but post-infusion observation consumes considerable clinical resources. This study evaluated whether post-infusion observation periods may be safely reduced or eliminated.</p><p><strong>Methods: </strong>A retrospective analysis included all IBD patients receiving infliximab or vedolizumab from January 2019 to December 2020 at Sygehus Lillebaelt, Denmark. Data included infusion counts, observation duration, timing and severity of reactions.</p><p><strong>Results: </strong>Among 380 patients receiving 3,847 infusions, 43 reactions (1.1%) occurred exclusively during infusions, mostly within the first 15 minutes. No reactions were reported after infusion had concluded.</p><p><strong>Conclusions: </strong>Routine post-infusion observation after infliximab and vedolizumab appears unnecessary. Reducing or eliminating this practice may optimise clinical resources without compromising patient safety.</p><p><strong>Funding: </strong>None.</p><p><strong>Trial registration: </strong>Not relevant.</p>\",\"PeriodicalId\":11119,\"journal\":{\"name\":\"Danish medical journal\",\"volume\":\"72 10\",\"pages\":\"\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-09-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Danish medical journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.61409/A03250206\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Danish medical journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.61409/A03250206","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
No post-infusion reactions after infliximab or vedolizumab.
Introduction: Biologic therapies like infliximab and vedolizumab effectively treat inflammatory bowel disease (IBD), but post-infusion observation consumes considerable clinical resources. This study evaluated whether post-infusion observation periods may be safely reduced or eliminated.
Methods: A retrospective analysis included all IBD patients receiving infliximab or vedolizumab from January 2019 to December 2020 at Sygehus Lillebaelt, Denmark. Data included infusion counts, observation duration, timing and severity of reactions.
Results: Among 380 patients receiving 3,847 infusions, 43 reactions (1.1%) occurred exclusively during infusions, mostly within the first 15 minutes. No reactions were reported after infusion had concluded.
Conclusions: Routine post-infusion observation after infliximab and vedolizumab appears unnecessary. Reducing or eliminating this practice may optimise clinical resources without compromising patient safety.
期刊介绍：
The Danish Medical Journal (DMJ) is a general medical journal. The journal publish original research in English – conducted in or in relation to the Danish health-care system. When writing for the Danish Medical Journal please remember target audience which is the general reader. This means that the research area should be relevant to many readers and the paper should be presented in a way that most readers will understand the content.
DMJ will publish the following articles:
• Original articles
• Protocol articles from large randomized clinical trials
• Systematic reviews and meta-analyses
• PhD theses from Danish faculties of health sciences
• DMSc theses from Danish faculties of health sciences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
